Bristol-Myers Squibb Co. is conducting several early stage studies on CGRP antagonists and other companies are testing or may begin development of similar compounds as well.
If drug development can be made faster and cheaper in every stage save the last human testing there will be a huge incentive to clear that hurdle, too.